The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.
Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.
Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.
The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.